Apraclonidine
Glaucoma · Rx
RxGlaucomaGlaucoma Alpha Purple cap
| Strength | 0.5%, 1% |
|---|---|
| Typical quantity | 5-10 mL bottle (generic; mostly in-office use for IOP spikes) |
| Cash cost / month | Low · ~$0-20 |
| Drug class | Alpha-2 adrenergic agonist (less selective) |
| Mechanism of action | Alpha-2 agonist (with some alpha-1 activity); reduces aqueous production. Does not cross the blood-brain barrier well, so fewer CNS effects than brimonidine, but marked tachyphylaxis limits chronic use. |
| Indication / reason for use | Prevention/control of post-laser IOP spikes (1% before and after ALT/PI/capsulotomy); short-term adjunct while awaiting surgery. Also a diagnostic aid for Horner syndrome (reverses anisocoria). |
| Usual adult dosing | Peri-laser: 1 drop 1 h before and immediately after. Short-term adjunct: 1 drop TID (rarely useful beyond a month). |
| Preservative | BAK 0.01% |
| Contact lenses | Remove lenses; reinsert after 15 minutes. |
| Common / important adverse effects | Lid retraction, mydriasis, conjunctival blanching then hyperemia, high rate of allergic blepharoconjunctivitis, dry mouth. |
| Contraindications & cautions | MAO inhibitor use; severe cardiovascular disease. |
| Pregnancy / lactation | Limited data; short-term use only. |
| Pregnancy category (older labels) | No letter category on the current label. From DailyMed labels, checked Nov 2026. |
| Trade names | Iopidine |
| Practice notes | In suspected Horner syndrome, apraclonidine reverses the anisocoria (the denervation-supersensitive miotic pupil dilates). |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.